title: Effects of internal carotid administration of MPTP on rat brain and blood-brain barrier.
abstract: Unlike primates, rats are resistant to systemic 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) neurotoxicity, but direct infusion of MPTP into rat substantia nigra causes specific destruction of dopaminergic neurons. We now demonstrate that rats are resistant to MPTP neurotoxicity even when MPTP is injected directly into the brain circulation. Injection of 1-3.5 mg of MPTP into the internal carotid artery of Wistar rats causes no behavioral or motor abnormalities and small, but significant, dopamine loss in the ipsilateral striatum. MPTP caused no changes in the levels of norepinephrine or serotonin in the cerebral cortex. Higher doses of intracarotid MPTP were lethal. Pretreatment with pargyline, a monoamine oxidase inhibitor, did not alter the mortality but prevented dopamine depletion. The high uptake and retention of MPTP by rat brain, yet its failure to cause major dopaminergic toxicity suggest that MPTP is rapidly metabolized in brain capillaries to 1-methyl-4-phenylpyridinium (MPP+) and other polar metabolites that have difficulty in traversing the blood-brain barrier. Sequestration of MPTP metabolites in brain capillary endothelial cells could result in their dysfunction. However, we found no defects in the ability of the blood-brain barrier to prevent the entry of vascular aminoisobutyric acid or horseradish peroxidase into brain in spite of morphologic evidence of endothelial changes and astrocytic swelling after intracarotid MPTP injections. Our results provide further evidence that the rat's resistance to systemic MPTP neurotoxicity is probably due to its unique blood-brain barrier properties.
authors.affiliation: Department of Neurology, University Hospitals of Cleveland, OH 44106.
authors.forename: N J
authors.initials: NJ
authors.lastname: Riachi
authors.forename: W D
authors.initials: WD
authors.lastname: Dietrich
authors.forename: S I
authors.initials: SI
authors.lastname: Harik
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000378:metabolism; D000621:Aminoisobutyric Acids; D000818:Animals; D015306:Biogenic Monoamines / Q000378:metabolism; D001812:Blood-Brain Barrier / Q000187:drug effects*; D001921:Brain / Q000187:drug effects*; D002199:Capillary Permeability / Q000187:drug effects; D002343:Carotid Artery, Internal; D004730:Endothelium, Vascular / Q000187:drug effects; D006735:Horseradish Peroxidase; D007269:Injections, Intra-Arterial; D020267:MPTP Poisoning; D008297:Male; D010293:Pargyline / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D014316:Tritium
chemical_list: D000621:Aminoisobutyric Acids; D015306:Biogenic Monoamines; D014316:Tritium; D010293:Pargyline; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D006735:Horseradish Peroxidase